Carbamazepine and valproic acid: effects on the serum lipids and liver functions in children

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology
• Biochemistry

Background:

• Epileptic children often require long-term antiepileptic drug (AED) therapy.
• AEDs can potentially affect lipid metabolism and liver function.
• Understanding these effects is crucial for managing long-term health in pediatric epilepsy.

Purpose of the Study:

• To investigate the impact of carbamazepine and valproic acid on serum lipids and liver function tests in epileptic children.
• To compare the effects of these two common AEDs over a six-month treatment period.

Main Methods:

• A cohort of 38 epileptic children (mean age 8.6 years) was studied.
• Serum lipids and liver function tests were assessed at baseline, 2 months, and 6 months of AED therapy.
• Results were compared between children receiving carbamazepine (n=31) and valproic acid (n=7).

Main Results:

• While overall differences between drug groups were not significant, carbamazepine significantly increased total cholesterol, LDL, total cholesterol/HDL ratio, and gamma glutamyl transferase (P < 0.05).
• These changes were observed during the treatment period in the carbamazepine group.
• Valproic acid did not lead to significant alterations in serum lipid levels or liver function tests.

Conclusions:

• Carbamazepine treatment in epileptic children can adversely affect serum lipid profiles, potentially promoting atherosclerosis.
• Valproic acid appears to be metabolically neutral regarding serum lipids and liver function in this pediatric cohort.
• Long-term monitoring of lipid profiles is recommended for children on carbamazepine therapy.